Cagrilintide-Semaglutide Improved HbA1c More Than Semaglutide in T2DM Tags hBA1c GLP-1 agonists SGLT-2 Inhibitor Read more about Cagrilintide-Semaglutide Improved HbA1c More Than Semaglutide in T2DM
ADA 2026: PG-102 Lowered HbA1c With Biweekly and Monthly Dosing Tags FBS GLP-1 agonists hBA1c Read more about ADA 2026: PG-102 Lowered HbA1c With Biweekly and Monthly Dosing
ADA 2026: Semaglutide Improved Glycemic Control in Kidney Transplant Recipients Tags hBA1c GLP-1 agonists Read more about ADA 2026: Semaglutide Improved Glycemic Control in Kidney Transplant Recipients
ADA 2026: Semaglutide Improved Glycemic Control in Advanced CKD Tags Diabetic Nephropathy CKD hBA1c GLP-1 agonists Read more about ADA 2026: Semaglutide Improved Glycemic Control in Advanced CKD
ADA 2026: Oral Ribupatide Achieved Up to 11.9% Weight Loss at 26 Weeks Tags GLP-1 agonists Read more about ADA 2026: Oral Ribupatide Achieved Up to 11.9% Weight Loss at 26 Weeks
Semaglutide and Tirzepatide Showed Comparable Weight Loss at Select Doses in T2DM Tags GLP-1 agonists Read more about Semaglutide and Tirzepatide Showed Comparable Weight Loss at Select Doses in T2DM
ADA 2026: GLP-1 RAs Were Linked to Lower DFU Risk in T2DM Tags Diabetic foot. GLP-1 agonists Read more about ADA 2026: GLP-1 RAs Were Linked to Lower DFU Risk in T2DM
Oral HRS-7535 Improved HbA1c in T2DM on Metformin Tags Hypoglycemia hBA1c GLP-1 agonists Biguanide Read more about Oral HRS-7535 Improved HbA1c in T2DM on Metformin
GLP-1RA Therapy Was Not Associated With OA Risk in T2DM Tags GLP-1 agonists Read more about GLP-1RA Therapy Was Not Associated With OA Risk in T2DM
Semaglutide Users Had Higher NAION Risk in T2DM Tags Nonarteritic Ischemic Optic Neuropathy GLP-1 agonists Read more about Semaglutide Users Had Higher NAION Risk in T2DM